Patients and age-matched healthy donors
| Characteristic . | Diagnosis . | Healthy donors . | |||
|---|---|---|---|---|---|
| FL . | eMZL . | CLL . | MGUS . | ||
| No. | 11 | 7 | 9 | 6 | 18 |
| Median age, y (range) | 65 (37-68) | 65 (27-77) | 66 (42-80) | 53 (43-66) | 62.5 (28-76) |
| Sex, male/female | 8/3 | 4/3 | 8/1 | 3/3 | 5/13 |
| Stage* | |||||
| 0 | NA | NA | 9 | ||
| I | 1 | 2 | 0 | ||
| II | 1 | 3 | 0 | ||
| III | 7 | 0 | 0 | ||
| IV | 2 | 2 | 0 | ||
| B symptoms present | 4 | 0 | 0 | 0 | NA |
| IPI risk | |||||
| 0/5 | 1 | 1 | NA | NA | NA |
| 1/5 | 2 | 4 | NA | NA | NA |
| 2/5 | 6 | 2 | NA | NA | NA |
| 3/5 | 1 | 0 | NA | NA | NA |
| 4/5 | 1 | 0 | NA | NA | NA |
| Comments | 3 H pylori+ | Leukocytes < 28/nL | |||
| Characteristic . | Diagnosis . | Healthy donors . | |||
|---|---|---|---|---|---|
| FL . | eMZL . | CLL . | MGUS . | ||
| No. | 11 | 7 | 9 | 6 | 18 |
| Median age, y (range) | 65 (37-68) | 65 (27-77) | 66 (42-80) | 53 (43-66) | 62.5 (28-76) |
| Sex, male/female | 8/3 | 4/3 | 8/1 | 3/3 | 5/13 |
| Stage* | |||||
| 0 | NA | NA | 9 | ||
| I | 1 | 2 | 0 | ||
| II | 1 | 3 | 0 | ||
| III | 7 | 0 | 0 | ||
| IV | 2 | 2 | 0 | ||
| B symptoms present | 4 | 0 | 0 | 0 | NA |
| IPI risk | |||||
| 0/5 | 1 | 1 | NA | NA | NA |
| 1/5 | 2 | 4 | NA | NA | NA |
| 2/5 | 6 | 2 | NA | NA | NA |
| 3/5 | 1 | 0 | NA | NA | NA |
| 4/5 | 1 | 0 | NA | NA | NA |
| Comments | 3 H pylori+ | Leukocytes < 28/nL | |||
NA indicates not applicable.
Staging for FL and eMZL was by Ann Arbor staging, and for CLL, by Rai stage.